COMPASS Pathways announces positive outcome of 25mg COMP360 psilocybin therapy as adjunct to SSRI antidepressants in… Dec 13, 2021
By The Numbers: Dispensary Owners And Non-Consumers Surveyed In Weedmaps’ 2021 Cannabis Data & Insights Report Dec 10, 2021
Awakn CEO Anthony Tennyson Predicts 2022 Will Be A Big Year For Institutional Investment In Psychedelics Dec 9, 2021
MindMed Engages in Productive Pre-Submission Meeting with FDA for Development of the MindMed Session Monitoring System Dec 9, 2021
